{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ruxolitinib+5+MG", "query": { "intervention": "Ruxolitinib 5 MG" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 59, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ruxolitinib+5+MG&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T20:32:33.170Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05998395", "title": "JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kohlmeier Degos Disease With Neurologic Involvement", "Kohlmeier-Degos Disease" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1, "start_date": "2023-09-28", "completion_date": "2025-02-28", "has_results": true, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-09-29T20:32:33.170Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05998395" }, { "nct_id": "NCT07424222", "title": "Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 16, "start_date": "2026-07-15", "completion_date": "2029-02-01", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-29T20:32:33.170Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07424222" }, { "nct_id": "NCT03117751", "title": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Erwinase®", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Asparaginase Erwinia chrysanthemi (recombinant)-rywn", "type": "DRUG" }, { "name": "Calaspargase Pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 790, "start_date": "2017-03-29", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-29T20:32:33.170Z", "location_count": 7, "location_summary": "Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03117751" }, { "nct_id": "NCT07249346", "title": "Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplasia", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Myeloablative conditioning regimen", "type": "DRUG" }, { "name": "Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hannah Choe, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2026-01-14", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-29T20:32:33.170Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07249346" }, { "nct_id": "NCT06936566", "title": "MAGIC Ruxolitinib for aGVHD", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Graft-versus-host Disease", "Allogeneic Bone Marrow Transplantation", "Adverse Effects" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Levine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2025-05-14", "completion_date": "2028-04-14", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-09-29T20:32:33.170Z", "location_count": 14, "location_summary": "Duarte, California • Tampa, Florida • Atlanta, Georgia + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06936566" }, { "nct_id": "NCT00639002", "title": "A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ruxolitinib 25 mg", "type": "DRUG" }, { "name": "Dexamethasone 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2008-03", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-09-29T20:32:33.170Z", "location_count": 3, "location_summary": "Highland, California • Boynton Beach, Florida • New York, New York", "locations": [ { "city": "Highland", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00639002" }, { "nct_id": "NCT00550043", "title": "A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "INCB018424", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2007-10", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2015-03-23", "last_synced_at": "2026-09-29T20:32:33.170Z", "location_count": 12, "location_summary": "Huntsville, Alabama • Upland, California • Gainesville, Florida + 9 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Upland", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Kalispell", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00550043" }, { "nct_id": "NCT06973668", "title": "A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AML" ], "interventions": [ { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "65 Years to 75 Years" }, "enrollment_count": 80, "start_date": "2025-07-22", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-09-29T20:32:33.170Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06973668" }, { "nct_id": "NCT01895842", "title": "Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2014-02", "completion_date": "2019-04-02", "has_results": false, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-09-29T20:32:33.170Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01895842" }, { "nct_id": "NCT01243944", "title": "Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Polycythemia Vera" ], "interventions": [ { "name": "ruxolitinib tablets", "type": "DRUG" }, { "name": "Best Available Therapy (BAT)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2010-10-27", "completion_date": "2018-02-09", "has_results": true, "last_update_posted_date": "2019-03-06", "last_synced_at": "2026-09-29T20:32:33.170Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Pomona, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Pomona", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01243944" } ] }